Akram J. Kadhim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Akram J. Kadhim has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abdulaziz Ibrahim
Pharmacological and Diagnostic Research Center (PDRC), Faculty of Pharmacy, Al-Ahliyya Amman University, P.O. Box 183, Amman 19328, Jordan
1 shared publication - Alaa Sanabrah
Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan
1 shared publication - Frezah Muhana
Pharmacological and Diagnostic Research Center (PDRC), Faculty of Pharmacy, Al-Ahliyya Amman University, P.O. Box 183, Amman 19328, Jordan
1 shared publication - Ibrahim Tawfiq
Faculty of Pharmacy, American University of Madaba, P.O. Box 2882, Amman 11821, Jordan
1 shared publication - Laila Mahmoud Matalqah
Department of Clinical Sciences, College of Pharmacy and Health Sciences (COPHS), Ajman University, Ajman P.O. Box 346, United Arab Emirates
1 shared publication - Mohamed El-Tanani
RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 841
In Vitro Antitumor Properties of Simvastatin-Loaded SBA-16 Mesoporous Nanoparticles Using Two- and Three-Dimensional Colorectal Spheroid Models
Background/objectives: Colorectal cancer (CRC) remains a cause of cancer-related mortality worldwide, with therapeutic progress hindered by poor tumor selectivity and acquired drug resistance. This study investigated the anticancer efficacy of simvastatin, administered as a free drug or encapsulated within mesoporous SBA-16 nanoparticles (NPs), against HT-29 colorectal cancer cells in two-dimensional monolayer and three-dimensional spheroid culture models. Methods: SBA-16 NPs achieved drug-loading efficiency of 73.83% and accelerated cumulative release of 91.93% within 30 min, compared to 35.24% for the free drug. Cell viability and proliferation were assessed via MTT and clonogenic assays, while interleukin-6 (IL-6) levels were measured by ELISA to evaluate anti-inflammatory activity. Results: Simvastatin-loaded SBA-16 NPs reduced the IC50 from 27.86 µg/mL to 4.43 µg/mL, representing a 6.29-fold enhancement in cytotoxic potency (p < 0.001), and significantly inhibited colony formation and suppressed IL-6 secretion, indicating modulation of inflammatory pathways implicated in tumor progression. In the 3D spheroid model, the nanoparticle formulation induced dose-dependent inhibition superior to the free drug. Conclusions: These findings demonstrate that SBA-16 nanocarriers substantially amplify simvastatin’s anticancer efficacy through improved drug solubilisation and rapid release kinetics under sink conditions, with possible—but not directly proven—enhanced cellular interaction/internalisation and modulation of tumor-associated inflammatory signaling. Direct uptake, penetration, mechanistic cell-death, normal-cell selectivity, and in vivo studies are warranted to confirm clinical applicability.
- 10 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 841
Open AccessIn Vitro Antitumor Properties of Simvastatin-Loaded SBA-16 Mesoporous Nanoparticles Using Two- and Three-Dimensional Colorectal Spheroid Models
Background/objectives: Colorectal cancer (CRC) remains a cause of cancer-related mortality worldwide, with therapeutic progress hindered by poor tumor selectivity and acquired drug resistance. This study investigated the anticancer efficacy of simvastatin, administered as a free drug or encapsulated within mesoporous SBA-16 nanoparticles (NPs), against HT-29 colorectal cancer cells in two-dimensional monolayer and three-dimensional spheroid culture models. Methods: SBA-16 NPs achieved drug-loading efficiency of 73.83% and accelerated cumulative release of 91.93% within 30 min, compared to 35.24% for the free drug. Cell viability and proliferation were assessed via MTT and clonogenic assays, while interleukin-6 (IL-6) levels were measured by ELISA to evaluate anti-inflammatory activity. Results: Simvastatin-loaded SBA-16 NPs reduced the IC50 from 27.86 µg/mL to 4.43 µg/mL, representing a 6.29-fold enhancement in cytotoxic potency (p < 0.001), and significantly inhibited colony formation and suppressed IL-6 secretion, indicating modulation of inflammatory pathways implicated in tumor progression. In the 3D spheroid model, the nanoparticle formulation induced dose-dependent inhibition superior to the free drug. Conclusions: These findings demonstrate that SBA-16 nanocarriers substantially amplify simvastatin’s anticancer efficacy through improved drug solubilisation and rapid release kinetics under sink conditions, with possible—but not directly proven—enhanced cellular interaction/internalisation and modulation of tumor-associated inflammatory signaling. Direct uptake, penetration, mechanistic cell-death, normal-cell selectivity, and in vivo studies are warranted to confirm clinical applicability.